Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690714 · ClinicalTrials.gov registry record · Phase 2
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
A Phase 2 study of Hypoplasminogenemia and Congenital Plasminogen Deficiency, sponsored by Prometic Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT02690714 is a Phase 2 study of Hypoplasminogenemia and Congenital Plasminogen Deficiency that has completed, run by Prometic Biotherapeutics. The registered enrollment target is 15 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02690714, a Phase 2 study of Hypoplasminogenemia and Congenital Plasminogen Deficiency, has completed, sponsored by Prometic Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult subjects with hypoplasminogenemia.
Conditions Studied
Interventions
- BIOLOGICAL Plasminogen (Human) intravenous
Study Locations (2)
Indiana
- Indiana Hemophilia and Thrombosis Center - Indianapolis
Sognsvannvejen 20
- Oslo University Hospital HF - Oslo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02690714
The ClinicalTrials.gov registry entry for NCT02690714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prometic Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypoplasminogenemia appearing as the primary indexed condition, and to 1 intervention - of which Plasminogen (Human) intravenous is the first listed.
NCT02690714 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, Sognsvannvejen 20.
Frequently Asked Questions
What is clinical trial NCT02690714 about?
NCT02690714 is a clinical study titled "A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia". This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult subjects with hypoplasminogenemia.
What is the current status of trial NCT02690714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-05-04. Estimated completion is 2018-10-08.
What conditions does trial NCT02690714 study?
This clinical trial studies the following conditions: Hypoplasminogenemia, Congenital Plasminogen Deficiency.
What interventions are being tested in trial NCT02690714?
The interventions under investigation include: Plasminogen (Human) intravenous (BIOLOGICAL).
Who is sponsoring clinical trial NCT02690714?
This trial is sponsored by Prometic Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690714 being conducted?
This trial has 2 study locations across Indiana, Sognsvannvejen 20. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.